AssetMark’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-62
Closed -$137 – 2032
2023
Q4
$137 Buy
+62
New +$132 ﹤0.01% 1803
2016
Q1
– Sell
-13
Closed – – 1305
2015
Q4
$0 Buy
13
+9
+225% +$88 ﹤0.01% 1434
2015
Q3
$0 Buy
+4
New +$63 ﹤0.01% 798

Other funds holding LAB

AssetMark's LAB Position: Q1 2024 in Review

AssetMark sold out of Standard BioTools (LAB) in Q1 2024, closing a stake of 62 shares — an estimated $137 sold.

AssetMark first reported a position in LAB in Q3 2015 and held it in 3 quarters. The position peaked at $137 in Q4 2023. 146 funds tracked by Wall St. Rank hold LAB as of Q1 2024.

  • AssetMark reported no remaining Standard BioTools position as of Q1 2024 after selling out during the quarter.
  • AssetMark sold 62 Standard BioTools shares in Q1 2024, an estimated $137.
  • AssetMark first reported a position in Standard BioTools in Q3 2015 and held it in 3 quarters.
  • AssetMark's Standard BioTools position peaked at $137 in Q4 2023.
  • 146 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2024.

Based on AssetMark's 13F filing for Q1 2024, filed 7 May 2024.